EUVIMEDEUVIMED entdecken
Klinische Studie (Phase III)Randomisierte kontrollierte StudieMultizentrische StudieOpen Access

Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study

Se Hoon Park, Yen-Hwa Chang, Jae Lyun Lee, Toni K Choueiri, Go Kimura, Jinsoo Chung, Naoya Masumori, Kazuo Nishimura, Minoru Kato, Haruaki Kato, Kazuyuki Numakura, Chao-Hsiang Chang und 7 weitere

Cancer Research and Treatment · 2025

DOI: 10.4143/crt.2025.365 ↗

Kurz gefasst

Klinische Studie (Phase III) in der Zeitschrift Cancer Research and Treatment, 2025. Verfasst von Se Hoon Park und 18 weiteren Autor:innen. Beteiligte Einrichtung: Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea. Hauptthemen laut MEDLINE: Antibodies, Monoclonal, Humanized, Carcinoma, Renal Cell, Kidney Neoplasms, Antineoplastic Agents, Immunological. Die Arbeit wurde bisher 1-mal zitiert (Crossref). Der Volltext ist frei in PubMed Central verfügbar. Gefördert von: Merck Sharp & Dohme LLC, Merck & Co., Inc..

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

PURPOSE: Adjuvant pembrolizumab improved disease-free survival (DFS) and overall survival (OS) versus placebo in participants with renal cell carcinoma (RCC) at increased risk of recurrence after nephrectomy in the global phase 3 KEYNOTE-564 study. This post hoc subgroup analysis evaluated the efficacy and safety of adjuvant pembrolizumab in East Asian (Japan, South Korea, and Taiwan) participants enrolled in KEYNOTE-564. MATERIALS AND METHODS: Eligible participants were randomly assigned 1:1 to receive adjuvant pembrolizumab 200 mg or placebo intravenously every 3 weeks for ≤ 17 cycles. The primary endpoint was DFS by investigator assessment. OS was a key secondary endpoint. Safety was a secondary endpoint. RESULTS: The East Asian subgroup included 126 participants (pembrolizumab, n=58; placebo, n=68). Median follow-up was 62.1 months (range, 49.6 to 73.0 months). Hazard ratio for DFS with pembrolizumab versus placebo was 0.70 (95% confidence interval 0.41 to 1.20). Median DFS was not reached with pembrolizumab versus 58.8 months with placebo; estimated 48-month rate was 61.3% versus 51.2%. Hazard ratio for OS was 0.47 (95% confidence interval, 0.15 to 1.49). Median OS was not reached with pembrolizumab and placebo; estimated 48-month rate was 94.8% versus 91.2%. Treatment-related adverse events occurred in 70.7% of participants (29.3% grade 3 or 4) receiving pembrolizumab and 36.8% of participants (0.0% grade 3 or 4) receiving placebo. No pembrolizumab-related deaths occurred. CONCLUSION: In the KEYNOTE-564 East Asian subgroup, adjuvant pembrolizumab provided DFS and OS benefits versus placebo and had a safety profile consistent with the global results. These results further support pembrolizumab as adjuvant treatment for East Asian patients with RCC at increased risk of recurrence after nephrectomy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Antibodies, Monoclonal, HumanizedCarcinoma, Renal CellKidney NeoplasmsAntineoplastic Agents, ImmunologicalHumansMaleFemaleMiddle AgedAgedChemotherapy, AdjuvantAdultTreatment OutcomeEast Asian People

Stichwörter der Autor:innen

AsiaImmunoadjuvantPD-1 inhibitorPembrolizumabRenal cell carcinoma

Substanzen

pembrolizumabAntibodies, Monoclonal, HumanizedAntineoplastic Agents, Immunological

Autor:innen und Institutionen

  • Division of Hematology-Oncology, Department of Medicine, Samsung Medical Center, Sungkyunkwan University School of Medicine, Seoul, Korea.
  • Department of Urology, Taipei Veterans General Hospital, Taipei, Taiwan.
  • Department of Oncology, Asan Medical Center, University of Ulsan College of Medicine, Seoul, Korea.
  • Department of Medical Oncology, Lank Center for Genitourinary Oncology at Dana-Farber Cancer Institute, Boston, MA, USA.
  • Department of Urology, Nippon Medical School Hospital, Tokyo, Japan.
  • Department of Urology, National Cancer Center, Goyang, Korea.

Förderung

  • Merck Sharp & Dohme LLC
  • Merck & Co., Inc.

Zitieren

APA

Park, S. H., Chang, Y. H., Lee, J. L., Choueiri, T. K., Kimura, G., Chung, J., Masumori, N., Nishimura, K., Kato, M., Kato, H., Numakura, K., Chang, C. H., Anai, S., Tsunemori, H., Chen, C. H., Lin, J., Elfiky, A., Burgents, J. E., & Kitamura, H. (2025). Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study. Cancer Research and Treatment. https://doi.org/10.4143/crt.2025.365

Vancouver

Park SH, Chang YH, Lee JL, Choueiri TK, Kimura G, Chung J, et al. Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study. Cancer Research and Treatment. 2025. doi:10.4143/crt.2025.365

BibTeX
@article{Park2025,
  author = {Park, Se Hoon and Chang, Yen-Hwa and Lee, Jae Lyun and Choueiri, Toni K and Kimura, Go and Chung, Jinsoo and Masumori, Naoya and Nishimura, Kazuo and Kato, Minoru and Kato, Haruaki and Numakura, Kazuyuki and Chang, Chao-Hsiang and Anai, Satoshi and Tsunemori, Hiroyuki and Chen, Chung-Hsin and Lin, Jianxin and Elfiky, Aymen and Burgents, Joseph E and Kitamura, Hiroshi},
  title = {Adjuvant Pembrolizumab Versus Placebo for Renal Cell Carcinoma in the East Asian Subgroup of the Phase 3 KEYNOTE-564 Study},
  journal = {Cancer Research and Treatment},
  year = {2025},
  doi = {10.4143/crt.2025.365}
}
Kostenlos starten →